APPARATUS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS
First Claim
Patent Images
1. A drug-delivery device, comprising:
- a first reservoir for containing a first liquid that comprises or consists essentially of a first therapeutic agent;
a second reservoir for containing a second liquid that comprises or consists essentially of a second therapeutic agent different from the first therapeutic agent; and
at least one cannula, in fluid communication with the first and second reservoirs, for separately delivering the first and second liquids to a patient.
2 Assignments
0 Petitions
Accused Products
Abstract
In various embodiments, a drug-delivery device includes one or more reservoirs that may each contain a therapeutic agent for delivery to a patient.
-
Citations
39 Claims
-
1. A drug-delivery device, comprising:
-
a first reservoir for containing a first liquid that comprises or consists essentially of a first therapeutic agent; a second reservoir for containing a second liquid that comprises or consists essentially of a second therapeutic agent different from the first therapeutic agent; and at least one cannula, in fluid communication with the first and second reservoirs, for separately delivering the first and second liquids to a patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A drug-delivery device, comprising:
-
a first reservoir for containing a first liquid that comprises or consists essentially of a first therapeutic agent; a second reservoir for containing a second liquid that comprises or consists essentially of a second therapeutic agent different from the first therapeutic agent; memory for storing a drug-delivery regimen; and a microprocessor for controlling a delivery of the first and second liquids to a patient through at least one cannula based on an execution of the stored drug-delivery regimen. - View Dependent Claims (21, 22, 23, 24, 25)
-
-
26. A drug-delivery device, comprising:
-
a reservoir containing a liquid that comprises a therapeutic agent selected from the group consisting of acetazolamide, betaxolol, bevacizumab, bimatoprost, brimonidine, brinzolamide, carbidopa, carteolol, cidofovir, cyclosporine, dorzolamide, epinephrine, a growth factor, irinotecan, ketorolac tromethamine, ketotifen fumarate, latanoprost, levobetaxolol, levobunolol, levodopa, levofloxacin, loratadine, loteprednol etabonate, metipranolol, naphazoline, ofloxacin, pegaptanib, pemirolast, pheniramine maleate, pilocarpine, pseudoephedrine, ranibizumab, a steroid, timolol, travoprost, trifluridine, tumor necrosis factor blocker, unoprostone isopropyl, valganciclovir, verteporfin, vitravene, a drug that prevents beta amyloid deposition in the retina, a drug that prevents beta amyloid deposition in the brain, an anti-human complement activation blocker that blocks complement H activation in the eye, and siRNA molecules; and a cannula in fluid communication with the reservoir, the cannula having an outlet for delivering the therapeutic agent to a patient.
-
-
27. A method for treating an ophthalmic condition, comprising:
-
a) providing a drug-delivery device comprising; i) a first reservoir; ii) a second reservoir; and iii) at least one cannula, in fluid communication with the first and second reservoirs, the at least one cannula having an outlet; b) attaching the drug-delivery device onto the conjunctiva of a patient'"'"'s eye such that the outlet of the at least one cannula penetrates the conjunctiva; c) filling the first reservoir with a first liquid that comprises or consists essentially of a first therapeutic agent; d) filling the second reservoir with a second liquid that comprises or consists essentially of a second therapeutic agent, the second therapeutic agent being different from the first therapeutic agent; and e) separately delivering the first and second therapeutic agents to the patient via the outlet of the at least one cannula. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
-
38. A method for treating an ophthalmic condition, comprising:
-
implanting a drug-delivery device in a patient'"'"'s eye; and filling the drug-delivery device with a liquid that comprises a therapeutic agent selected from the group consisting of acetazolamide, betaxolol, bevacizumab, bimatoprost, brimonidine, brinzolamide, carbidopa, carteolol, cidofovir, cyclosporine, dorzolamide, epinephrine, ketorolac tromethamine, ketotifen fumarate, latanoprost, levobetaxolol, levobunolol, levodopa, levofloxacin, loratadine, loteprednol etabonate, metipranolol, naphazoline, ofloxacin, pegaptanib, pemirolast, pheniramine maleate, pilocarpine, pseudoephedrine, ranibizumab, a steroid, timolol, travoprost, trifluridine, unoprostone isopropyl, valganciclovir, verteporfin, vitravene, a drug that prevents beta amyloid deposition in the retina, an anti-human complement activation blocker that blocks complement H activation in the eye, and siRNA molecules.
-
-
39. A method for treating a cancerous condition, comprising:
-
implanting a drug-delivery device near a patient'"'"'s tumor; and filling the drug-delivery device with a combination of drugs selected from the group consisting of i) bevacizumab and CPT-11;
ii) ranibizumab and CPT-11;
iii) letrozole and tamoxifen;
iv) doxorubicin and docetaxel;
v) bevacizumab and any chemotherapy drug;
vi) gemcitabine and CP-870,893;
vii) PF-3512676 and a cytotoxic chemotherapy drug;
viii) bevacizumab and paclitaxel;
ix) docetaxel and sunitinib;
x) bevacizumab and sunitinib;
xi) lapatinib and letrozole;
xii) ixabepilone and capecitabine; and
xiii) paclitaxel protein-bound and a taxane.
-
Specification